| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Sarah Gheuens | Med | 2026-10-26 | 7,866 | $25.01 | $196.73kBuy |
| Sarah Gheuens | Med | 2026-10-26 | 7,866 | $37.69 | $296.47kSell |
| Sarah Gheuens | Med | 2026-10-22 | 500 | $25.01 | $12.51kBuy |
| Sarah Gheuens | Med | 2026-10-22 | 500 | $37.52 | $18.76kSell |
| Sarah Gheuens | Med | 2026-10-21 | 1,489 | $37.53 | $55.88kSell |
| Sarah Gheuens | Med | 2026-10-21 | 1,489 | $25.01 | $37.24kBuy |
| Sarah Gheuens | Med | 2026-08-04 | 30,000 | $30.48 | $914.40kSell |
| Sarah Gheuens | Chief Medical Officer | 2026-07-01 | 4,007 | $37.56 | $150.50kSell |
| Brian Goff | Chief Executive Officer | 2026-04-02 | 12,472 | $34.71 | $432.90kSell |
| Krishnan Viswanadhan | Chief Corp Dev Strategy | 2026-04-02 | 2,959 | $34.71 | $102.71kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Celgene European Investment Co LLC | 9.83% | 5,867,279 | $179.25M | Insider |
| Robert Nelsen | 6.65% | 3,969,968 | $121.28M | Insider |
| Arch Venture Fund VII LP | 5.17% | 3,088,590 | $94.36M | Insider |
| Celgene Corp | 4.16% | 2,486,157 | $75.95M | Insider |
| Flagship Ventures Fund 2007 LP | 3.23% | 1,930,369 | $58.97M | Insider |
| Tak W. Mak | 0.91% | 545,454 | $16.66M | Insider |
| David P. Schenkein | 0.34% | 205,324 | $6.27M | Insider |
| Brian Goff | 0.31% | 184,508 | $5.64M | Insider |
| Kevin P. Starr | 0.31% | 184,386 | $5.63M | Insider |
| Jacqualyn A. Fouse | 0.26% | 154,156 | $4.71M | Insider |